12:32 PM
 | 
Jul 13, 2018
 |  BC Week In Review  |  Company News  |  Deals

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea.

ABL will receive $4.3 million up front and be eligible for $550 million in...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >